超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

普羅吉生物 Protgen
北京普羅吉生物科技發(fā)展有限公司 (Protgen Ltd.) 成立于 2004 年 8 月，是由留學歸國人員創(chuàng)立的研發(fā)型高新技術企業(yè)。公司的研發(fā)及高層管理團隊由多位留學歐美的資深學者和企業(yè)家組成，具有豐富的重組蛋白藥物研發(fā)和生物技術公司管理運行經(jīng)驗。目前，公司員工本科以上學歷達到 90% 以上，其中擁有博士和碩士學位的達 40% 以上。

普羅吉公司，是國家發(fā)展和改革委員會批準建立的 “抗腫瘤蛋白質(zhì)藥物國家工程實驗室” 的共建單位，與清華大學有著密切合作，建立了高效和日趨成熟的產(chǎn)、學、研相結合的生物技術成果快速轉化機制和模式。公司致力于研發(fā)具有自主知識產(chǎn)權和國際競爭力的重組蛋白質(zhì)藥物、抗體藥物和腫瘤診斷試劑，在蛋白質(zhì)藥物規(guī)模化制備方面具有一系列國際領先的核心專有技術。

公司具有卓越的科研項目管理經(jīng)驗和先進的技術研發(fā)水平，承擔并參與了多項國家級科研課題。“十五”期間公司參與完成國家 863 課題一項，目前正承擔一項 863 課題，并參與一項 863 課題，主持“十一五”計劃“重大新藥創(chuàng)制”一項，參與“十一五”計劃“重大新藥創(chuàng)制”兩項。公司已申請了五項 PCT 發(fā)明專利，分別進入四十一個國家和地區(qū)，其中一項已在中國獲得授權。

長期以來，公司受到了北京市委、市政府，北京市科委及中關村管委會等部門的大力支持。公司首席科學家入選中央 2009 年度第一批“千人計劃”；2010 年 4 月，公司榮獲中關村國家自主創(chuàng)新示范區(qū)“2009 年重大科技成果產(chǎn)業(yè)化突出貢獻單位”稱號；同年，公司成為“北京生物醫(yī)藥產(chǎn)業(yè)跨越發(fā)展工程”（G20工程）第一批企業(yè)，并入選 2010 年中關村“瞪羚計劃”首批重點培育企業(yè)。

公司力爭在未來五年內(nèi)，發(fā)揮重組蛋白規(guī)模化制備和蛋白質(zhì)藥物研發(fā)的優(yōu)勢，面向海內(nèi)外生物醫(yī)藥市場，努力發(fā)展成為國內(nèi)一流、國際知名的生物制藥公司。


Protgen Ltd., as a new research high-technology company located in the Zhongguancun Science and Technology Park, was founded in August, 2004 by returned oversea scholars. The senior management team, who are in charge of the R & D and management, consist of several oversea scholars and enterprisers. At present, 90% employees of the company have bachelor degrees and 40% of them have doctoral degrees.

Located in the Zhongguancun Biomedical Park, Protgen Ltd. is the collaborator of the National Engineering Laboratory for Anti-tumor Protein Therapeutics authorized by the National Develop and Reform Commission. Protgen dedicates in developing recombinant protein drugs with intellectual property rights and international competitiveness, protein drugs, antibodies, diagnosis kits and service on recombinant proteins (protein purification, refolding; antibody preparation protein drug production).

Protgen believes efficiency, seriouseness, deploitation and innovation. According to our excellent project experience, Protgen has been participating many national science projects, such as 863, etc. Now Protgen has filed 4 PCT inventions and patents, one of which has been authorized in China.

Protgen is supported by many government departments. The chief scientist is selected to the “One-Thousand Talent Project”. On 23th April, Protgen is announced to be one of the G20 enterprises.

In the next five years, based on its advantages in protein science, Protgen will explore and seek for oversea market and make its best to become an internationally well-known biomedical company.